anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Consultants Gambit

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 39,432
Current window 34,411-34,440
Pages 1,315
Rows per page 30
Arc: Consultants Gambitclear collectionreset all
18 30 60

Arc

34,411-34,440 of 39,432

filter-aware
29
The slide uses a two-column layout to separate milestones for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
30
The slide uses a standard pharmaceutical pipeline table format to communicate clinical progress and regulatory milestones.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
31
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
32
The slide uses a wave-like visual to represent market segments and their associated dollar values.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
34
The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
35
The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
36
The slide uses a two-column layout to contrast clinical outcomes for two different indications, followed by a row of competitor product logos and financial metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
37
The chart illustrates deepening responses in patients treated with NXC-201 over time.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
38
The slide uses a combination of biological pathway diagrams, pharmacokinetic data, and efficacy metrics to demonstrate the therapeutic advantage of IMX-110.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a numbered list format to present clinical milestones and market opportunities.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
40
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
41
Uses icon-based visualization to represent market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a process flow diagram to illustrate dose escalation steps.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
43
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS) across three dosage groups.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
44
The table highlights specific adverse events (CRS and ICANS) within a red dashed box.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
45
Highlights NXC-201's lower fludarabine dose (25 mg vs 30 mg) and Carvykti's longer infusion window (5-7 days vs 5 days).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
46
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
47
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
48
The slide uses a bar chart to contrast the combined annual sales of two groups of oncology drugs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
49
The slide uses three distinct bar charts to compare IMX-110 performance against standard of care or competitor drugs in preclinical mouse models.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
50
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
51
Includes survival curves (Kaplan-Meier style), tumor imaging, and median survival metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
52
Includes clinical trial data visualization with PFS (Progression Free Survival) and PD/PR thresholds.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a scatter plot to map clinical trials and a table to detail standard-of-care metrics by line of therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
54
The slide compares clinical outcomes for patients across different lines of treatment, emphasizing high disease control and zero drug-related toxicity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
55
Includes logos for BeiGene and Novartis.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
56
Includes comparative size diagram of IMX-111 vs IgG antibody, bar chart of GLUT1 expression by tissue, box plot of GLUT1 expression by stage, and Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
57
Includes two sets of charts: tumor volume line charts and survival curves.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
58
Includes multiple citations and diagrams of molecular mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit